RecruitingPhase 1NCT05206877

Topical Insulin for Glaucoma

Topical Insulin for Glaucoma and Optic Neuropathies


Sponsor

Stanford University

Enrollment

52 participants

Start Date

Apr 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether eye drops containing insulin can help protect and improve vision in people with certain types of optic nerve damage. The optic nerve connects your eye to your brain, and when it's damaged, it can cause vision loss. Researchers believe insulin may have a protective effect on these nerve cells. **You may be eligible if...** - You have been diagnosed with glaucoma, NAION (a type of sudden optic nerve damage caused by poor blood flow), or optic disc drusen (deposits on the optic nerve) - You are able to give informed consent **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have other eye conditions causing significant vision loss (such as retinal disease or severe inflammation) - You have been diagnosed with diabetes or glucose intolerance - You are unable to reliably complete vision field tests - You cannot attend the required follow-up appointments Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGInsulin, 4 units

Topical insulin 100 U/ml, 1 drop per day

DRUGInsulin, 20 units

Topical insulin 500 U/ml, 1 drop per day

DRUGinsulin, 4 units twice daily

1 drop of low dose insulin twice daily.

DRUGinsulin, 20 units twice daily

1 drop of high dose insulin twice daily

DRUGinsulin, 4 units three times daily

1 drop of low dose insulin three times daily.

DRUGinsulin, 20 units three times daily

1 drop of high dose insulin three times daily.


Locations(1)

Byers Eye Institute at Stanford University

Palo Alto, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05206877


Related Trials